Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis
Authors: Nides, Mitchell; Glover, Elbert D.; Reus, Victor I.; Christen, Arden G.; Make, Barry J.; Billing, Clare B.; Williams, Kathryn E.
Source: American Journal of Health Behavior, Volume 32, Number 6, November 2008 , pp. 664-675(12)
Publisher: PNG Publications
Abstract:Objectives: To evaluate varenicline's efficacy for smoking cessation versus bupropion SR and placebo and to explore whether factors typically predictive of abstinence influence varenicline's efficacy versus placebo, as measured by the week 912 continuous abstinence rate (CAR912).Methods: Smokers in 2 randomized, placebo-controlled trials received varenicline 1 mg BID (n696), bupropion SR 150 mg BID (n671), or placebo (n685) for 12 weeks. Nontreatment followup lasted 40 weeks.Results: CAR912 was greater for varenicline (44.0) versus bupropion SR (29.7; P<0.0001) and placebo (17.7; P<0.0001). CAR912 for varenicline versus placebo was not affected by age, gender, or nicotine dependence level.Conclusions: Varenicline was more efficacious than bupropion SR or placebo. Varenicline's efficacy versus placebo was not influenced by factors predictive of abstinence.
Document Type: Research article
Publication date: 2008-11-01
- The American Journal of Health Behavior seeks to improve the quality of life through multidisciplinary health efforts in fostering a better understanding of the multidimensional nature of both individuals and social systems as they relate to health behaviors.
The Journal aims to provide a comprehensive understanding of the impact of personal attributes, personality characteristics, behavior patterns, social structure, and processes on health maintenance, health restoration, and health improvement; to disseminate knowledge of holistic, multidisciplinary approaches to designing and implementing effective health programs; and to showcase health behavior analysis skills that have been proven to affect health improvement and recovery.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Review Board
- Reprints and Permissions
- ingentaconnect is not responsible for the content or availability of external websites